Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

An audit of the management of elderly patients with glioblastoma in the UK: have recent trial results changed treatment?

Chong MY, Lorimer CF, Mehta S, Ibrahim E, Brock J, McBain C, McLoone P, Chalmers AJ.

CNS Oncol. 2019 Dec 1;8(4):CNS47. doi: 10.2217/cns-2019-0017. Epub 2019 Dec 10.

2.

Mesothelioma cells depend on the anti-apoptotic protein Bcl-xL for survival and are sensitized to ionizing radiation by BH3-mimetics.

Jackson MR, Ashton M, Koessinger AL, Dick C, Verheij M, Chalmers AJ.

Int J Radiat Oncol Biol Phys. 2019 Nov 28. pii: S0360-3016(19)34068-4. doi: 10.1016/j.ijrobp.2019.11.029. [Epub ahead of print]

PMID:
31786278
3.

Radiation Responses of 2D and 3D Glioblastoma Cells: A Novel, 3D-specific Radioprotective Role of VEGF/Akt Signaling through Functional Activation of NHEJ.

Gomez-Roman N, Chong MY, Chahal SK, Caragher SP, Jackson MR, Stevenson KH, Dongre SA, Chalmers AJ.

Mol Cancer Ther. 2020 Feb;19(2):575-589. doi: 10.1158/1535-7163.MCT-18-1320. Epub 2019 Oct 31.

PMID:
31672763
4.

Targeting DNA repair in gliomas.

Beckta JM, Bindra RS, Chalmers AJ.

Curr Opin Neurol. 2019 Dec;32(6):878-885. doi: 10.1097/WCO.0000000000000760.

PMID:
31592790
5.

CTRad 10 Years On: From 10-point Plan to Top 10 Achievements.

Chalmers AJ, Chan C, Sebag-Montefiore D; Executive Group of the National Cancer Research Institute's Clinical and Translational Radiotherapy Research Working Group (CTRad).

Clin Oncol (R Coll Radiol). 2020 Jan;32(1):9-12. doi: 10.1016/j.clon.2019.09.043. Epub 2019 Sep 19. No abstract available.

PMID:
31543302
6.

Stacked in-plane histology for quantitative validation of non-invasive imaging biomarkers: Application to an infiltrative brain tumour model.

Al-Mubarak H, Vallatos A, Gallagher L, Birch JL, Gilmour L, Foster JE, Chalmers AJ, Holmes WM.

J Neurosci Methods. 2019 Oct 1;326:108372. doi: 10.1016/j.jneumeth.2019.108372. Epub 2019 Jul 23.

PMID:
31348965
7.

Focused very high-energy electron beams as a novel radiotherapy modality for producing high-dose volumetric elements.

Kokurewicz K, Brunetti E, Welsh GH, Wiggins SM, Boyd M, Sorensen A, Chalmers AJ, Schettino G, Subiel A, DesRosiers C, Jaroszynski DA.

Sci Rep. 2019 Jul 25;9(1):10837. doi: 10.1038/s41598-019-46630-w.

8.

Assembling the brain trust: the multidisciplinary imperative in neuro-oncology.

Ludmir EB, Mahajan A, Ahern V, Ajithkumar T, Alapetite C, Bernier-Chastagner V, Bindra RS, Bishop AJ, Bolle S, Brown PD, Carrie C, Chalmers AJ, Chang EL, Chung C, Dieckmann K, Esiashvili N, Gandola L, Ghia AJ, Gondi V, Grosshans DR, Harrabi SB, Horan G, Indelicato DJ, Jalali R, Janssens GO, Krause M, Laack NN, Laperriere N, Laprie A, Li J, Marcus KJ, McGovern SL, Merchant TE, Merrell KW, Padovani L, Parkes J, Paulino AC, Schwarz R, Shih HA, Souhami L, Sulman EP, Taylor RE, Thorp N, Timmermann B, Wheeler G, Wolden SL, Woodhouse KD, Yeboa DN, Yock TI, Kortmann RD, McAleer MF.

Nat Rev Clin Oncol. 2019 Aug;16(8):521-522. doi: 10.1038/s41571-019-0235-z. No abstract available.

PMID:
31150024
9.

Patient-specific 3D-printed glioblastomas.

Gomez-Roman N, Chalmers AJ.

Nat Biomed Eng. 2019 Jul;3(7):498-499. doi: 10.1038/s41551-019-0379-2. No abstract available.

PMID:
31148599
10.

A DNA Repair and Cell-Cycle Gene Expression Signature in Primary and Recurrent Glioblastoma: Prognostic Value and Clinical Implications.

Gobin M, Nazarov PV, Warta R, Timmer M, Reifenberger G, Felsberg J, Vallar L, Chalmers AJ, Herold-Mende CC, Goldbrunner R, Niclou SP, Van Dyck E.

Cancer Res. 2019 Mar 15;79(6):1226-1238. doi: 10.1158/0008-5472.CAN-18-2076. Epub 2019 Jan 23.

11.

Glioblastoma's Next Top Model: Novel Culture Systems for Brain Cancer Radiotherapy Research.

Caragher S, Chalmers AJ, Gomez-Roman N.

Cancers (Basel). 2019 Jan 4;11(1). pii: E44. doi: 10.3390/cancers11010044. Review.

12.

Quantitative histopathologic assessment of perfusion MRI as a marker of glioblastoma cell infiltration in and beyond the peritumoral edema region.

Vallatos A, Al-Mubarak HFI, Birch JL, Galllagher L, Mullin JM, Gilmour L, Holmes WM, Chalmers AJ.

J Magn Reson Imaging. 2019 Aug;50(2):529-540. doi: 10.1002/jmri.26580. Epub 2018 Dec 19.

PMID:
30569620
13.

Evaluation of four different small animal radiation plans on tumour and normal tissue dosimetry in a glioblastoma mouse model.

Rutherford A, Stevenson K, Tulk A, Chalmers AJ.

Br J Radiol. 2019 Mar;92(1095):20180469. doi: 10.1259/bjr.20180469. Epub 2018 Nov 7.

PMID:
30362815
14.

A Novel Small-Molecule Inhibitor of MRCK Prevents Radiation-Driven Invasion in Glioblastoma.

Birch JL, Strathdee K, Gilmour L, Vallatos A, McDonald L, Kouzeli A, Vasan R, Qaisi AH, Croft DR, Crighton D, Gill K, Gray CH, Konczal J, Mezna M, McArthur D, Schüttelkopf AW, McConnell P, Sime M, Holmes WM, Bower J, McKinnon HJ, Drysdale M, Olson MF, Chalmers AJ.

Cancer Res. 2018 Nov 15;78(22):6509-6522. doi: 10.1158/0008-5472.CAN-18-1697. Epub 2018 Oct 2.

15.

Radiation-Induced Transformation of Immunoregulatory Networks in the Tumor Stroma.

Martinez-Zubiaurre I, Chalmers AJ, Hellevik T.

Front Immunol. 2018 Jul 26;9:1679. doi: 10.3389/fimmu.2018.01679. eCollection 2018. Review.

16.

Practice-changing radiation therapy trials for the treatment of cancer: where are we 150 years after the birth of Marie Curie?

Thompson MK, Poortmans P, Chalmers AJ, Faivre-Finn C, Hall E, Huddart RA, Lievens Y, Sebag-Montefiore D, Coles CE.

Br J Cancer. 2018 Aug;119(4):389-407. doi: 10.1038/s41416-018-0201-z. Epub 2018 Jul 31. Review.

17.

Replication Stress Drives Constitutive Activation of the DNA Damage Response and Radioresistance in Glioblastoma Stem-like Cells.

Carruthers RD, Ahmed SU, Ramachandran S, Strathdee K, Kurian KM, Hedley A, Gomez-Roman N, Kalna G, Neilson M, Gilmour L, Stevenson KH, Hammond EM, Chalmers AJ.

Cancer Res. 2018 Sep 1;78(17):5060-5071. doi: 10.1158/0008-5472.CAN-18-0569. Epub 2018 Jul 5.

18.

Health economic evaluation of a serum-based blood test for brain tumour diagnosis: exploration of two clinical scenarios.

Gray E, Butler HJ, Board R, Brennan PM, Chalmers AJ, Dawson T, Goodden J, Hamilton W, Hegarty MG, James A, Jenkinson MD, Kernick D, Lekka E, Livermore LJ, Mills SJ, O'Neill K, Palmer DS, Vaqas B, Baker MJ.

BMJ Open. 2018 May 24;8(5):e017593. doi: 10.1136/bmjopen-2017-017593.

19.

An 18F-Labeled Poly(ADP-ribose) Polymerase Positron Emission Tomography Imaging Agent.

Zmuda F, Blair A, Liuzzi MC, Malviya G, Chalmers AJ, Lewis D, Sutherland A, Pimlott SL.

J Med Chem. 2018 May 10;61(9):4103-4114. doi: 10.1021/acs.jmedchem.8b00138. Epub 2018 Apr 19.

20.

SYSTEMS-2: A randomised phase II study of radiotherapy dose escalation for pain control in malignant pleural mesothelioma.

Ashton M, O'Rourke N, Macleod N, Laird B, Stobo J, Kelly C, Alexander L, Franks K, Moore K, Currie S, Valentine R, Chalmers AJ.

Clin Transl Radiat Oncol. 2017 Nov 21;8:45-49. doi: 10.1016/j.ctro.2017.11.004. eCollection 2018 Jan.

21.

PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status.

Fulton B, Short SC, James A, Nowicki S, McBain C, Jefferies S, Kelly C, Stobo J, Morris A, Williamson A, Chalmers AJ.

Clin Transl Radiat Oncol. 2017 Nov 21;8:12-16. doi: 10.1016/j.ctro.2017.11.003. eCollection 2018 Jan.

22.

GBM radiosensitizers: dead in the water…or just the beginning?

Bindra RS, Chalmers AJ, Evans S, Dewhirst M.

J Neurooncol. 2017 Sep;134(3):513-521. doi: 10.1007/s11060-017-2427-7. Epub 2017 Jul 31. Review.

PMID:
28762004
23.

Multiple boli arterial spin labeling for high signal-to-noise rodent brain perfusion imaging.

Vallatos A, Gilmour L, Chalmers AJ, Holmes WM.

Magn Reson Med. 2018 Feb;79(2):1020-1030. doi: 10.1002/mrm.26706. Epub 2017 May 17.

PMID:
28516482
24.

PP2A Inhibitor PME-1 Drives Kinase Inhibitor Resistance in Glioma Cells.

Kaur A, Denisova OV, Qiao X, Jumppanen M, Peuhu E, Ahmed SU, Raheem O, Haapasalo H, Eriksson J, Chalmers AJ, Laakkonen P, Westermarck J.

Cancer Res. 2016 Dec 1;76(23):7001-7011. Epub 2016 Sep 26.

25.

The Challenges Faced in Developing Novel Drug Radiation Combinations in Non-small Cell Lung Cancer.

Harrow S, Hanna GG, Faivre-Finn C, McDonald F, Chalmers AJ.

Clin Oncol (R Coll Radiol). 2016 Nov;28(11):720-725. doi: 10.1016/j.clon.2016.08.004. Epub 2016 Aug 31. Review.

PMID:
27591000
26.

A novel 3D human glioblastoma cell culture system for modeling drug and radiation responses.

Gomez-Roman N, Stevenson K, Gilmour L, Hamilton G, Chalmers AJ.

Neuro Oncol. 2017 Feb 1;19(2):229-241. doi: 10.1093/neuonc/now164.

27.

Glioblastoma in the elderly - How do we choose who to treat?

Lorimer CF, Saran F, Chalmers AJ, Brock J.

J Geriatr Oncol. 2016 Nov;7(6):453-456. doi: 10.1016/j.jgo.2016.07.005. Epub 2016 Jul 29.

PMID:
27478132
28.

Clinical development of new drug-radiotherapy combinations.

Sharma RA, Plummer R, Stock JK, Greenhalgh TA, Ataman O, Kelly S, Clay R, Adams RA, Baird RD, Billingham L, Brown SR, Buckland S, Bulbeck H, Chalmers AJ, Clack G, Cranston AN, Damstrup L, Ferraldeschi R, Forster MD, Golec J, Hagan RM, Hall E, Hanauske AR, Harrington KJ, Haswell T, Hawkins MA, Illidge T, Jones H, Kennedy AS, McDonald F, Melcher T, O'Connor JP, Pollard JR, Saunders MP, Sebag-Montefiore D, Smitt M, Staffurth J, Stratford IJ, Wedge SR; NCRI CTRad Academia-Pharma Joint Working Group.

Nat Rev Clin Oncol. 2016 Oct;13(10):627-42. doi: 10.1038/nrclinonc.2016.79. Epub 2016 Jun 1.

29.

NOTCH blockade combined with radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma.

Yahyanejad S, King H, Iglesias VS, Granton PV, Barbeau LM, van Hoof SJ, Groot AJ, Habets R, Prickaerts J, Chalmers AJ, Eekers DB, Theys J, Short SC, Verhaegen F, Vooijs M.

Oncotarget. 2016 Jul 5;7(27):41251-41264. doi: 10.18632/oncotarget.9275.

30.

Hypoxia-inducible factor 1 alpha is required for the tumourigenic and aggressive phenotype associated with Rab25 expression in ovarian cancer.

Gomez-Roman N, Sahasrabudhe NM, McGregor F, Chalmers AJ, Cassidy J, Plumb J.

Oncotarget. 2016 Apr 19;7(16):22650-64. doi: 10.18632/oncotarget.7998.

31.

Science in Focus: Combining Radiotherapy with Inhibitors of the DNA Damage Response.

Chalmers AJ.

Clin Oncol (R Coll Radiol). 2016 May;28(5):279-82. doi: 10.1016/j.clon.2016.01.035. Epub 2016 Feb 23. No abstract available.

PMID:
26920234
32.

ESTRO-ACROP guideline "target delineation of glioblastomas".

Niyazi M, Brada M, Chalmers AJ, Combs SE, Erridge SC, Fiorentino A, Grosu AL, Lagerwaard FJ, Minniti G, Mirimanoff RO, Ricardi U, Short SC, Weber DC, Belka C.

Radiother Oncol. 2016 Jan;118(1):35-42. doi: 10.1016/j.radonc.2015.12.003. Epub 2016 Jan 6.

PMID:
26777122
33.

Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma.

Tardito S, Oudin A, Ahmed SU, Fack F, Keunen O, Zheng L, Miletic H, Sakariassen PØ, Weinstock A, Wagner A, Lindsay SL, Hock AK, Barnett SC, Ruppin E, Mørkve SH, Lund-Johansen M, Chalmers AJ, Bjerkvig R, Niclou SP, Gottlieb E.

Nat Cell Biol. 2015 Dec;17(12):1556-68. doi: 10.1038/ncb3272. Epub 2015 Nov 23.

34.

Synthesis and Evaluation of a Radioiodinated Tracer with Specificity for Poly(ADP-ribose) Polymerase-1 (PARP-1) in Vivo.

Zmuda F, Malviya G, Blair A, Boyd M, Chalmers AJ, Sutherland A, Pimlott SL.

J Med Chem. 2015 Nov 12;58(21):8683-93. doi: 10.1021/acs.jmedchem.5b01324. Epub 2015 Oct 27.

35.

Selective Inhibition of Parallel DNA Damage Response Pathways Optimizes Radiosensitization of Glioblastoma Stem-like Cells.

Ahmed SU, Carruthers R, Gilmour L, Yildirim S, Watts C, Chalmers AJ.

Cancer Res. 2015 Oct 15;75(20):4416-28. doi: 10.1158/0008-5472.CAN-14-3790. Epub 2015 Aug 17.

36.

A novel 18F-labelled high affinity agent for PET imaging of the translocator protein.

Blair A, Zmuda F, Malviya G, Tavares AAS, Tamagnan GD, Chalmers AJ, Dewar D, Pimlott SL, Sutherland A.

Chem Sci. 2015 Aug 1;6(8):4772-4777. doi: 10.1039/c5sc01647a. Epub 2015 May 27.

37.

Complementary use of bioluminescence imaging and contrast-enhanced micro-computed tomography in an orthotopic brain tumor model.

Yahyanejad S, Granton PV, Lieuwes NG, Gilmour L, Dubois L, Theys J, Chalmers AJ, Verhaegen F, Vooijs M.

Mol Imaging. 2014;13. doi: 10.2310/7290.2014.00038.

PMID:
25743108
38.

Limited mitochondrial permeabilization causes DNA damage and genomic instability in the absence of cell death.

Ichim G, Lopez J, Ahmed SU, Muthalagu N, Giampazolias E, Delgado ME, Haller M, Riley JS, Mason SM, Athineos D, Parsons MJ, van de Kooij B, Bouchier-Hayes L, Chalmers AJ, Rooswinkel RW, Oberst A, Blyth K, Rehm M, Murphy DJ, Tait SWG.

Mol Cell. 2015 Mar 5;57(5):860-872. doi: 10.1016/j.molcel.2015.01.018. Epub 2015 Feb 19. Erratum in: Mol Cell. 2015 Jun 4;58(5):900.

39.

Abrogation of radioresistance in glioblastoma stem-like cells by inhibition of ATM kinase.

Carruthers R, Ahmed SU, Strathdee K, Gomez-Roman N, Amoah-Buahin E, Watts C, Chalmers AJ.

Mol Oncol. 2015 Jan;9(1):192-203. doi: 10.1016/j.molonc.2014.08.003. Epub 2014 Aug 24.

40.

mTOR inhibition and levels of the DNA repair protein MGMT in T98G glioblastoma cells.

Smalley S, Chalmers AJ, Morley SJ.

Mol Cancer. 2014 Jun 8;13:144. doi: 10.1186/1476-4598-13-144.

41.

Differential sensitivity of Glioma stem cells to Aurora kinase A inhibitors: implications for stem cell mitosis and centrosome dynamics.

Mannino M, Gomez-Roman N, Hochegger H, Chalmers AJ.

Stem Cell Res. 2014 Jul;13(1):135-43. doi: 10.1016/j.scr.2014.05.001. Epub 2014 May 11.

42.

The potential of PARP inhibitors in neuro-oncology.

Carruthers R, Chalmers AJ.

CNS Oncol. 2012 Sep;1(1):85-97. doi: 10.2217/cns.12.13. Review.

43.

DNA repair and resistance to topoisomerase I inhibitors: mechanisms, biomarkers and therapeutic targets.

Alagoz M, Gilbert DC, El-Khamisy S, Chalmers AJ.

Curr Med Chem. 2012;19(23):3874-85. Review.

PMID:
22788763
44.

Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets.

Gilbert DC, Chalmers AJ, El-Khamisy SF.

Br J Cancer. 2012 Jan 3;106(1):18-24. doi: 10.1038/bjc.2011.498. Epub 2011 Nov 22. Review.

45.

Radioresistance of glioma stem cells: intrinsic characteristic or property of the 'microenvironment-stem cell unit'?

Mannino M, Chalmers AJ.

Mol Oncol. 2011 Aug;5(4):374-86. doi: 10.1016/j.molonc.2011.05.001. Epub 2011 May 20. Review.

46.

A UK-wide survey of follow-up practices for patients with high-grade glioma treated with radical intent.

Catt SL, Anderson JL, Chalmers AJ, Fallowfield LJ.

J Eval Clin Pract. 2011 Feb;17(1):1-6. doi: 10.1111/j.1365-2753.2009.01292.x. Epub 2010 Dec 8.

PMID:
21143347
47.

Overcoming resistance of glioblastoma to conventional cytotoxic therapies by the addition of PARP inhibitors.

Chalmers AJ.

Anticancer Agents Med Chem. 2010 Sep;10(7):520-33. Review.

PMID:
20879987
48.

Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets.

Chalmers AJ, Lakshman M, Chan N, Bristow RG.

Semin Radiat Oncol. 2010 Oct;20(4):274-81. doi: 10.1016/j.semradonc.2010.06.001. Review.

PMID:
20832020
49.

Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair.

Löser DA, Shibata A, Shibata AK, Woodbine LJ, Jeggo PA, Chalmers AJ.

Mol Cancer Ther. 2010 Jun;9(6):1775-87. doi: 10.1158/1535-7163.MCT-09-1027. Epub 2010 Jun 8.

50.

Evaluating novel radiation techniques for the treatment of cerebral metastases.

Chalmers AJ.

Br J Radiol. 2010 Feb;83(986):98-100. doi: 10.1259/bjr/15790337. No abstract available.

Supplemental Content

Loading ...
Support Center